Japanese Encephalitis - Pipeline Review, H1 2020

  • Life Sciences
  • 30 April 2020
  • 46 Pages
  • Formats:    
  • Report Code: 24WT-3566

Japanese Encephalitis Pipeline Review H1 - Overview

Japanese Encephalitis - Pipeline Review, H1 2020

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Japanese Encephalitis - Pipeline Review, H1 2020, provides an overview of the Japanese Encephalitis (Infectious Disease) pipeline landscape.

Japanese encephalitis is a viral disease that infects animals and humans. It is caused by a flavivirus that affects the membranes around the brain. It is transmitted by mosquitoes. Symptoms include fever, headache, muscle pain, diarrhea, seizures, muscle weakness and paralysis. Treatment targets relief of symptoms like pain relievers and anticonvulsants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Japanese Encephalitis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Japanese Encephalitis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Japanese Encephalitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Japanese Encephalitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical, Discovery and Unknown stages are 2, 2, 5, 1 and 1 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively.

Japanese Encephalitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Japanese Encephalitis (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Japanese Encephalitis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Japanese Encephalitis (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Japanese Encephalitis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Japanese Encephalitis (Infectious Disease)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Japanese Encephalitis (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Japanese Encephalitis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Japanese Encephalitis - Overview
Japanese Encephalitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Japanese Encephalitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Japanese Encephalitis - Companies Involved in Therapeutics Development
Abivax SA
Adimmune Corp
BioNet- Asia Co Ltd
Cadila Healthcare Ltd
Ennaid Therapeutics LLC
Fab’entech SA
Indian Immunologicals Ltd
Medigen Inc
Shandong Hengye Biotech Co Ltd
Sinovac Biotech Ltd
Vabiotech
Japanese Encephalitis - Drug Profiles
ABX-196 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FDX-000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Japanese encephalitis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Japanese encephalitis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Japanese encephalitis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Japanese encephalitis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Japanese encephalitis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Japanese encephalitis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Japanese encephalitis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Japanese encephalitis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Japanese encephalitis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Japanese encephalitis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies for Japanese Encephalitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit NS5 for Japanese Encephalitis and Viral Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides for Japanese Encephalitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Japanese Encephalitis - Dormant Projects
Japanese Encephalitis - Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables

Number of Products under Development for Japanese Encephalitis, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Japanese Encephalitis - Pipeline by Abivax SA, H1 2020

Japanese Encephalitis - Pipeline by Adimmune Corp, H1 2020

Japanese Encephalitis - Pipeline by BioNet- Asia Co Ltd, H1 2020

Japanese Encephalitis - Pipeline by Cadila Healthcare Ltd, H1 2020

Japanese Encephalitis - Pipeline by Ennaid Therapeutics LLC, H1 2020

Japanese Encephalitis - Pipeline by Fab?entech SA, H1 2020

Japanese Encephalitis - Pipeline by Indian Immunologicals Ltd, H1 2020

Japanese Encephalitis - Pipeline by Medigen Inc, H1 2020

Japanese Encephalitis - Pipeline by Shandong Hengye Biotech Co Ltd, H1 2020

Japanese Encephalitis - Pipeline by Sinovac Biotech Ltd, H1 2020

Japanese Encephalitis - Pipeline by Vabiotech, H1 2020

Japanese Encephalitis - Dormant Projects, H1 2020

Japanese Encephalitis - Discontinued Products, H1 2020List of Figures

Number of Products under Development for Japanese Encephalitis, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Targets, H1 2020

Number of Products by Stage and Targets, H1 2020

Number of Products by Mechanism of Actions, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020
CHOOSE YOUR BUYING OPTION

NEED A HELP?

Submit your research need or query below

+91 9169162030 (Asia)
help@primemarketreports.com